
Didier Jutras-Aswad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6450759/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014, 55, 791-802.	5.1	766
2	The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among streetâ€drug users. Addiction, 2012, 107, 1318-1327.	3.3	149
3	Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 395-412.	3.2	142
4	Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics, 2015, 12, 807-815.	4.4	127
5	Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans. Journal of Addiction Medicine, 2015, 9, 204-210.	2.6	94
6	Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Substance Abuse: Research and Treatment, 2015, 9, SART.S25081.	0.9	78
7	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. International Journal of Drug Policy, 2022, 99, 103381.	3.3	75
8	Intentional cannabis use to reduce crack cocaine use in a Canadian setting: A longitudinal analysis. Addictive Behaviors, 2017, 72, 138-143.	3.0	67
9	Sustained Drug Use Changes After Hepatitis C Screening and Counseling Among Recently Infected Persons Who Inject Drugs: A Longitudinal Study. Clinical Infectious Diseases, 2014, 58, 755-761.	5.8	65
10	Associations of substance use patterns with attempted suicide among persons who inject drugs: Can distinct use patterns play a role?. Drug and Alcohol Dependence, 2015, 147, 208-214.	3.2	35
11	Cannabis-Dependence Risk Relates to Synergism between Neuroticism and Proenkephalin SNPs Associated with Amygdala Gene Expression: Case-Control Study. PLoS ONE, 2012, 7, e39243.	2.5	34
12	Modulation of the Endocannabinoid System: Vulnerability Factor and New Treatment Target for Stimulant Addiction. Frontiers in Psychiatry, 2013, 4, 109.	2.6	34
13	Visits to primary care physicians among persons who inject drugs at high risk of hepatitis <scp>C</scp> virus infection: room for improvement. Journal of Viral Hepatitis, 2015, 22, 792-799.	2.0	33
14	Reversing the Atypical Valuation of Drug and Nondrug Rewards in Smokers Using Multimodal Neuroimaging. Biological Psychiatry, 2017, 82, 819-827.	1.3	33
15	Epidemiology of Injection Drug Use. Canadian Journal of Psychiatry, 2016, 61, 136-144.	1.9	31
16	Psychosis Following Excessive Ingestion of Energy Drinks in a Patient With Schizophrenia. American Journal of Psychiatry, 2010, 167, 353-353.	7.2	30
17	Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placeboâ€controlled trial. Addiction, 2021, 116, 2431-2442.	3.3	30
18	High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention. International Journal of Drug Policy, 2017, 47, 61-68.	3.3	24

#	Article	IF	CITATIONS
19	Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. Cmaj, 2019, 191, E462-E468.	2.0	24
20	Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. American Journal of Psychiatry, 2022, 179, 726-739.	7.2	23
21	"l love having benzos after my coke shotâ€! The use of psychotropic medication among cocaine users in downtown Montreal. International Journal of Drug Policy, 2017, 49, 15-23.	3.3	22
22	The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. Contemporary Clinical Trials, 2018, 69, 21-27.	1.8	22
23	The evolving drug epidemic of prescription opioid injection and its association with HCV transmission among people who inject drugs in Montréal, Canada. Addiction, 2019, 114, 366-373.	3.3	22
24	Social Robot Interventions in Mental Health Care and Their Outcomes, Barriers, and Facilitators: Scoping Review. JMIR Mental Health, 2022, 9, e36094.	3.3	22
25	Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment. Psychiatry Research, 2020, 286, 112890.	3.3	21
26	Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?. International Journal of Drug Policy, 2019, 72, 69-76.	3.3	19
27	Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada. Drug and Alcohol Dependence, 2020, 206, 107744.	3.2	19
28	Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review. Journal of Dual Diagnosis, 2020, 16, 191-207.	1.2	19
29	Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychological Medicine, 2023, 53, 3858-3868.	4.5	19
30	A systematic review of technology-based psychotherapeutic interventions for decreasing cannabis use in patients with psychosis. Psychiatry Research, 2020, 288, 112940.	3.3	18
31	Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. International Journal of Drug Policy, 2017, 47, 239-243.	3.3	17
32	How to help homeless youth suffering from first episode psychosis and substance use disorders? The creation of a new intensive outreach intervention team. Psychiatry Research, 2019, 273, 603-612.	3.3	17
33	Licit and illicit substance use among people who inject drugs and the association with subsequent suicidal attempt. Addiction, 2015, 110, 1636-1643.	3.3	16
34	Anxiety, mood disorders and injection risk behaviors among cocaine users: Results from the COSMO study. American Journal on Addictions, 2015, 24, 654-660.	1.4	15
35	A Functional 3′UTR Polymorphism (rs2235749) of Prodynorphin Alters microRNA-365 Binding in Ventral Striatonigral Neurons to Influence Novelty Seeking and Positive Reward Traits. Neuropsychopharmacology, 2016, 41, 2512-2520.	5.4	15
36	Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada. Canadian Journal of Psychiatry, 2019, 64, 82-87.	1.9	15

#	Article	IF	CITATIONS
37	Examining the link between psychological distress, mental health disorders and sharing behaviors among cocaine users. Addictive Behaviors, 2016, 62, 54-59.	3.0	12
38	Examining the link between cocaine binging and individual, social and behavioral factors among street-based cocaine users. Addictive Behaviors, 2017, 68, 66-72.	3.0	12
39	A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders. Expert Review of Neurotherapeutics, 2021, 21, 779-791.	2.8	12
40	Gambling Problems Among Community Cocaine Users. Journal of Gambling Studies, 2016, 32, 1039-1053.	1.6	11
41	Cigarette smoking may modify the association between cannabis use and adiposity in males. Pharmacology Biochemistry and Behavior, 2015, 135, 121-127.	2.9	10
42	Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies. European Neuropsychopharmacology, 2021, 51, 106-131.	0.7	10
43	Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention. International Journal of Drug Policy, 2015, 26, 970-975.	3.3	9
44	Cannabis Use Correlates of Syringe Sharing among Injection Drug Users. American Journal on Addictions, 2010, 19, 231-237.	1.4	8
45	Substance Use and Misuse. Canadian Journal of Psychiatry, 2016, 61, 134-135.	1.9	8
46	Association between Binge Drug use and Suicide Attempt among People who Inject Drugs. Substance Abuse, 2018, 39, 315-321.	2.3	8
47	Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. Psychopharmacology, 2022, 239, 1211-1230.	3.1	8
48	Cannabis and cue-induced craving in cocaine-dependent individuals: A pilot study. Addictive Behaviors, 2017, 73, 4-8.	3.0	7
49	Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada. Journal of Viral Hepatitis, 2019, 26, 1413-1422.	2.0	7
50	Association between mental health service utilisation and sharing of injection material among people who inject drugs in Montreal, Canada. Addictive Behaviors, 2019, 96, 175-182.	3.0	7
51	Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs. American Journal of Preventive Medicine, 2020, 58, 845-853.	3.0	7
52	Assessing the current state of medical education on cannabis in Canada: Preliminary findings from Quebec. Paediatrics and Child Health, 2020, 25, S29-S33.	0.6	7
53	Changes in Alcohol Habits Among Workers During the Confinement of COVID-19: Results of a Canadian Cross-Sectional Survey. Substance Abuse: Research and Treatment, 2021, 15, 117822182110332.	0.9	7
54	Technology-Based Psychological Interventions for Young Adults With Early Psychosis and Cannabis Use Disorder: Qualitative Study of Patient and Clinician Perspectives. JMIR Formative Research, 2021, 5, e26562.	1.4	7

#	Article	IF	CITATIONS
55	Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. Neuropsychopharmacology, 2021, 46, 2101-2111.	5.4	7
56	Socioeconomic stability is associated with lower injection frequency among people with distinct trajectories of injection drug use. International Journal of Drug Policy, 2021, 94, 103205.	3.3	7
5 7	Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacology Biochemistry and Behavior, 2022, 216, 173376.	2.9	7
58	Treatment of Buprenorphine Precipitated Withdrawal: A Case Report. American Journal on Addictions, 2012, 21, 492-493.	1.4	6
59	A case of hypomania during nicotine cessation treatment with bupropion. Addiction Science & Clinical Practice, 2013, 8, 22.	2.6	6
60	Prevalence and correlates of prescription opioid residue injection. Drug and Alcohol Dependence, 2016, 166, 69-74.	3.2	6
61	Gender-specific associations between psychological distress and injecting risk behaviours among people who inject drugs in Montreal, Canada. International Journal of Drug Policy, 2021, 96, 103319.	3.3	6
62	Tranquilizer misuse among active cocaine users: Predictors of initiation. Drug and Alcohol Review, 2018, 37, 520-526.	2.1	5
63	A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder. International Clinical Psychopharmacology, 2018, 33, 268-273.	1.7	5
64	Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada. Addiction, 2019, 114, 1495-1503.	3.3	5
65	Preventive interventions targeting cannabis use and related harms in people with psychosis: A systematic review. Microbial Biotechnology, 2020, 15, 1439-1453.	1.7	5
66	Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada. International Journal of Drug Policy, 2021, 96, 103439.	3.3	5
67	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	1.9	5
68	Challenging CBD protective effect against THCâ€related outcomes: a call for robust clinical trials. Addiction, 2021, 116, 207-208.	3.3	4
69	Impact of a videoconferencing educational programme for the management of concurrent disorders on nurses' competency development and clinical practice: protocol for a convergent mixed methods study. BMJ Open, 2021, 11, e042875.	1.9	4
70	Effectiveness and experiences of the Extension for Community Healthcare Outcomes (ECHO) Model in developing competencies among healthcare professionals: a mixed methods systematic review protocol. Systematic Reviews, 2021, 10, 313.	5.3	4
71	Examining the Association Between Psychiatric Disorders and Cocaine Binges: Results From the COSMO Study. Journal of Addiction Medicine, 2018, 12, 136-142.	2.6	3
72	Discrete time measures versus trajectories of drinking frequency across adolescence as predictors of binge drinking in young adulthood: a longitudinal investigation. BMJ Open, 2020, 10, e035939.	1.9	3

#	Article	IF	CITATIONS
73	Prevalence, Characteristics, and Management of Chronic Noncancer Pain Among People Who Use Drugs: A Cross-Sectional Study. Pain Medicine, 2020, 21, 3205-3214.	1.9	3
74	Experiences and perceptions of nurses participating in an interprofessional, videoconference-based educational programme on concurrent mental health and substance use disorders: a qualitative study. BMC Nursing, 2022, 21, .	2.5	3
75	Portraying Persons Who Inject Drugs Recently Infected with Hepatitis C Accessing Antiviral Treatment: A Cluster Analysis. Hepatitis Research and Treatment, 2014, 2014, 1-7.	2.0	2
76	Le cannabis et ses effets délétères : pour un débat plus nuancé. Drogues, Santé Et Société, 0, 16	, б .в0.	2
77	Le marché légal du cannabis suite à sa légalisation au Canada : pistes de réflexion pour un encadrement efficace. Canadian Journal of Public Health, 2018, 109, 215-218.	2.3	2
78	Neurobiologie de la toxicomanieÂ: avancées récentes et nouvelles stratégies d'intervention. Drogues, Santé Et Société, 2009, 8, 27-73.	0.1	1
79	Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. Addiction Science & amp; Clinical Practice, 2015, 10, 6.	2.6	1
80	Implementation of a contingency approach for people with co-occurring substance use and psychiatric disorders: Acceptability and feasibility pilot study. Addictive Behaviors Reports, 2019, 10, 100223.	1.9	1
81	The Impact of Treatment Orders for Residential Treatment of Comorbid Severe Substance Use Disorders for Youth Suffering from Early Psychosis: a Case Series. International Journal of Mental Health and Addiction, 2021, 19, 2233-2244.	7.4	1
82	Management of psychosis in the context of cannabis use: Beyond the chicken or the egg question. Paediatrics and Child Health, 2020, 25, S5-S6.	0.6	1
83	Preferences for research design and treatment of comorbid depression among patients with an opioid use disorder: A cross-sectional discrete choice experiment. Drug and Alcohol Dependence, 2021, 226, 108857.	3.2	1
84	Psychometric properties of the French and English short form of the Protective Behavioural Strategies for Marijuana Scale in Canadian university students. BMJ Open, 2022, 12, e053715.	1.9	1
85	Buprenorphine Plasma Concentration in the Management of Opioid Dependence. American Journal on Addictions, 2011, 20, 304-305.	1.4	0